The results indicated a decrease in tumor size, growth rate, GLI2 messenger RNA, and protein expression, indicating that GLI2ASO may serve as a specific treatment for BLCA with promise for advancement (Raven et al., 2019). The gene discussed is GLI2; the disease is bladder transitional cell carcinoma.